Want to see VRDN full AI Analyst Report?
VRDN Stock Chart & Stats
$19.27
<$0.01(0.05%)
At close: 4:00 PM EDT
$19.27
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$13.18 - $34.29
Previous Close$19.2
Volume1.52M
Average Volume (3M)2.23M
Market Cap
$2.09B
Enterprise Value$1.42K
Total Cash (Recent Filing)$981.53M
Total Debt (Recent Filing)$242.16M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Nov 16, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding110,427,680
10 Day Avg. Volume1,692,252
30 Day Avg. Volume2,232,459
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.91Price Target Upside75.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.82
Revenue Forecast (FY)$21.42M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross ProfitA clear step-up to roughly $71M TTM revenue with solid gross profit signals the company is moving beyond purely pre-revenue R&D. Persistent top-line growth and healthy gross margins support future scaling, enabling investments in commercialization and improving the path to durable operating leverage as revenues expand.
Large Cash CushionNearly $1.0B of cash and equivalents provides meaningful runway to fund commercial launch activities and advance late-stage programs without immediate fundraising. This reduces short-term liquidity pressure, allowing management to execute commercialization and regulatory milestones with lower probability of disruptive near-term dilution.
Manufacturing & Commercial ReadinessA multi-year manufacturing agreement with WuXi secures scalable drug substance and product supply for veligrotug if approved. This materially de-risks commercial-scale manufacturing, shortens time-to-market, and supports reliable launch supply chains—key for consistent product availability and long-term commercial execution.
Bears Say
High Cash Burn & Large LossesSubstantial negative operating and free cash flow and a large TTM net loss reflect an ongoing cash burn profile. That persistent outflow pressures long-term sustainability absent steady commercial revenue growth, creating the need to manage expenses carefully or rely on capital markets until positive cash generation is achieved.
Reliance On External Financing / Dilution RiskRecent sizable financings, including convertible notes that can convert into millions of shares, highlight dependence on capital markets. Continued financing need risks dilution and alters capital structure, which can weigh on long-term per-share economics and investor returns if internal cash generation does not replace external funding.
Regulatory & Pipeline Execution RiskCommercial and revenue prospects hinge on successful regulatory approvals and clinical execution. A delayed or negative BLA outcome or trial setbacks for lead programs would materially extend cash burn, postpone sustainable revenue, and increase funding needs, making pipeline risk a central, enduring constraint until diversified approved products exist.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics, Inc.’s price range in the past 12 months?
Viridian Therapeutics, Inc. lowest stock price was $13.18 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics, Inc.’s market cap?
Viridian Therapeutics, Inc.’s market cap is $2.09B.
When is Viridian Therapeutics, Inc.’s upcoming earnings report date?
Viridian Therapeutics, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 101 days.
How were Viridian Therapeutics, Inc.’s earnings last quarter?
Viridian Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$1.035 by -$0.015.
Is Viridian Therapeutics, Inc. overvalued?
According to Wall Street analysts Viridian Therapeutics, Inc.’s price is currently Undervalued.
Does Viridian Therapeutics, Inc. pay dividends?
Viridian Therapeutics, Inc. does not currently pay dividends.
What is Viridian Therapeutics, Inc.’s EPS estimate?
Viridian Therapeutics, Inc.’s EPS estimate is -0.99.
How many shares outstanding does Viridian Therapeutics, Inc. have?
Viridian Therapeutics, Inc. has 110,427,680 shares outstanding.
What happened to Viridian Therapeutics, Inc.’s price movement after its last earnings report?
Viridian Therapeutics, Inc. reported an EPS of -$1.05 in its last earnings report, missing expectations of -$1.035. Following the earnings report the stock price went up 6.834%.
Which hedge fund is a major shareholder of Viridian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.91 (75.97% Upside)
$33.91 (75.97% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.37%
Trailing 12-Months
Company Description
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (VRDN) is a clinical-stage biotechnology company focused on developing potential treatments for thyroid eye disease (TED) and related autoimmune conditions. The company’s pipeline includes investigational monoclonal antibody candidates designed to inhibit insulin-like growth factor-1 receptor (IGF-1R), with programs such as VRDN-001 and VRDN-003 aimed at improving outcomes and dosing convenience for patients with TED. Viridian operates in the biotechnology/pharmaceutical sector and is primarily engaged in research and development rather than commercial product sales.
VRDN Stock 12 Month Forecast
Average Price Target
$33.91
▲(75.97% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
4.66% Insiders
26.25% Mutual Funds
3.67% Other Institutional Investors
49.85% Public Companies and
Individual Investors